
ãçãŸããçå®ãïŒ ãããªã倧éªå¯©ãç±³åœã«ãããã¯ã¯ãã³éçºãšå®å šæ§ã« ãæ·±å»ãã€æ·±å» ããªåé¡ãçºèŠ
å èšäºã¯ãã¡ããã/Click here to read the original article.
COVID-19ã¯ã¯ãã³ã«é¢ãããããããäžæ£è¡çºãã調æ»ããããã«2022幎12æã«æéããã倧éªå¯©ã¯ãç¯çœªè¡çºãçºèŠããªãã£ããããå«ççè¡çºãšéå«ççè¡çºã®å¢çç·ããã°ãã°ãŸããã ãã¹ãã³ãµãŒãšèŠå¶åœå±ã®åŽã®æ¬ºççã§äžæçãªè¡çºã®ãã¿ãŒã³ããçºèŠããã
ç«ææ¥ã«å ¬éãããå ±åæžã«ãããšããããªãå·ã®å€§éªå¯©ã¯ãç±³åœã«ãããã¯ã¯ãã³éçºãšå®å šæ§ç£èŠã®ããã»ã¹ã«é¢ããæ·±é ãã€æ·±å»ãªåé¡ããçºèŠããã
ãã³ã»ããµã³ãã£ã¹å·ç¥äºã¯2022幎12æãCOVID-19ã¯ã¯ãã³ã«é¢ãããããããäžæ£è¡çºãã調æ»ããããã«å€§éªå¯©ãæéãããéªå¯©å¡ãã¡ã¯COVID-19ã®è£œé å·¥çšã«é¢äžããèšŒäººã®ææžã確èªããäºæ èŽåãè¡ã£ãã
ãç¯çœªè¡çºã¯èŠã€ãããªãã£ããããã¹ãã³ãµãŒãšèŠå¶åœå±ã®åŽã«ãå«ççè¡çºãšéå«ççè¡çºã®å¢çç·ããã°ãã°è·šããæ¬ºççã§äžæçãªè¡çºã®ãã¿ãŒã³ãçºèŠãã ããšã圌ãã¯140ããŒãžã«åã¶å ±åæžã«èšããã
ãšåœŒãã¯ä»ãå ããïŒ
ãããããããéèŠãªããšã¯ã起蚎å¯èœãªç¯çœªè¡çºãèŠã€ãããªãã£ããããšãã£ãŠãåé¡ãèŠã€ãããªãã£ãããã§ã¯ãªããšããããšã§ããããã©ããããç±³åœã«ãããã¯ã¯ãã³éçºãšå®å šæ§ç£èŠã®ããã»ã¹ã«ã¯ãæ·±ãæ·±å»ãªåé¡ãããã
ããã®ãã¡ã®ããã€ãã¯ãCOVID-19ã®ãããªæ¥æ§ã®åé¡ã§ããã100幎ã«äžåºŠã®ãã³ãããã¯ã®ç¶æ³ä»¥å€ã§ã¯èµ·ããããããªãããããããã®ä»ã®åé¡ã¯ã·ã¹ãã çãªãã®ã§ããã誰ããä¿®æ£ãããŸã§äœåºŠã§ãç¹°ãè¿ãããã
éªå¯©å¡ã®çµè«ã«ã€ããŠãããŒã¿ãŒã»ããŒã·å士ã¯ããã£ãã§ã³ããŒãèªã«ããå·éã§æ£çŽãªè©äŸ¡ã ãšæãããšèªã£ãã
ããŒã·ã¯BMJèªã®äžçŽç·šéè ã§ãããã¡ãªãŒã©ã³ã倧åŠè¬åŠéšã®å»è¬åå»çãµãŒãã¹ç ç©¶åææã§ããã2024幎7æã圌ã¯ç±³åœé£åå»è¬åå±ïŒFDAïŒãšè£œè¬æ¥çã®ãå転ãã¢ãã«é¢ããBMJèªã®èª¿æ»ãçºè¡šããã
ãã®èª¿æ»ã«ãããè£œè¬æ¥çã«å°±è·ããFDAè·å¡ãããèå°è£ã§ ãFDAã«åœ±é¿ãäžããããšãèš±ãããŠããããšãæããã«ãªã£ãã
APéä¿¡ïŒAPïŒã®èšäºã¯ãCBSãã¥ãŒã¹ãMedPage Todayãå«ãè€æ°ã®å ±éæ©é¢ã«åãäžãããããç¯çœªè¡çºã®èšŒæ ã¯ãªã ããšããèŠåºãã§å ±éãããã
ãããããããã®èŠåºãã¯ãéªå¯©ã®èª¿æ»çµæã«ã€ããŠããµã³ãã£ã¹ãXã§èªã£ãå 容ãšã¯å¯Ÿç §çã§ãã£ãã
This morning, the Twenty-Second Statewide Grand Jury released its final report. This Grand Jury was tasked with investigating vaccine manufacturers and their production process for vaccines following the COVID-19 pandemic.
â Ron DeSantis (@GovRonDeSantis) January 7, 2025
While we are still reading through the report and itsâŠ
ããµã³ãã£ã¹æ°ã¯ããã®å ±åæžã¯å€§æè£œè¬äŒç€Ÿã®æ¬ºçãšé£èªåã®ãã¿ãŒã³ãæããã«ããŠããã ãã§ãªããããããã®ã¹ãã³ãµãŒã¯ã¯ã¯ãã³ã®è£œé ãšè²©å£²ã«äœååãã«ãã®çšéãæå ¥ããŠããã
ãçŸç¶ãç¶ããããšã¯ã§ããªãããã¢ã¡ãªã«åœæ°ã¯ã倧æè£œè¬äŒç€Ÿãé£éŠæ¿åºã®çšéãã©ã®ããã«äœ¿ã£ãŠãããã«ã€ããŠéææ§ã確ä¿ãããã¢ãªãŒããŒã§ã¯ãªããç£èŠåœ¹ãšããŠæŽ»åããèŠå¶æ©é¢ã«å€ããã
補è¬äŒç€Ÿãšç±³åœã®ã¯ã¯ãã³èŠå¶ããã»ã¹ã«é¢ãããçãŸããçå®ã
倧éªå¯©ã®å ±åæžã¯ããCOVID-19ã®ãã³ãããã¯ãè£œè¬æ¥çãã¯ã¯ãã³ã®æ¿èªãšèªå¯ã®ã·ã¹ãã ã«é¢ããããã€ãã®çãŸããçå® ãã匷調ããã
äŸãã°ããã¡ã€ã¶ãŒç€Ÿã¯åœåãäž»èŠãªèšåºè©Šéšã®ã²ãšã€ã§åŠå©Šã«çºçããæå®³äºè±¡ã«é¢ããæ å ±ãå ¬ã«ããªãã£ãã
ããããã®æå®³äºè±¡ã¯ãBNT162b2ã®å®å šæ§ãšæå¹æ§ã«é¢ããNEJMïŒãã¥ãŒã€ã³ã°ã©ã³ãã»ãžã£ãŒãã«ã»ãªãã»ã¡ãã£ã·ã³ïŒèªã«æ²èŒãããã©ã®è«æã«ããã©ããããããæ²èŒãããªãã£ãããæ³çã«ãã¡ã€ã¶ãŒç€Ÿã¯æçµçã«1001詊éšã®çµæãClinicalTrials.govã§å ¬è¡šããããšãèŠæ±ãããããã§ããã
ãŸããFDAã¯ãåºåãç¹å®ã®ã¯ã¯ãã³ã§ã¯ãªããã¯ã¯ãã³æ¥çš®äžè¬ã宣äŒããéããã¯ã¯ãã³äŒç€Ÿã«è²©å£²å¶éã課ããªãã£ãã
äŸãã°ã2021幎8æãã¢ããã¯å ã¢ã¹ãªãŒããèµ·çšããåºåãåºãããæ°çŸäžäººãå©ããã¯ã¯ãã³ãããã«ããã°ãç§ãã¡ã¯ç¥ã£ãŠãããããªäººçãžã®äžæ©ãèžã¿åºãããšãã§ããã®ã§ã"ã
調æ»çµæã«åºã¥ããéªå¯©å¡å£ã¯ç±³åœã®ã¯ã¯ãã³è£œé ãšèŠå¶ã®ããã»ã¹ãã©ã®ããã«å€ããã¹ããã«ã€ããŠã以äžã®ãããªæèšãè¡ã£ãïŒ
è£œè¬æ¥çãšFDAãçŸç 管çäºé²ã»ã³ã¿ãŒãªã©ã®æ¿åºæ©é¢ãšã®éã® ãå転ã㢠ãåé¡ã«åœæ°ãåãçµãŸãªããã°ãªããªãã
ã¯ã¯ãã³ã¡ãŒã«ãŒã¯ãå®å šæ§ã®ã·ã°ãã«ãçºèŠããã確èªããããŸã§åŸ ã€ã®ã§ã¯ãªããçºèŠããã確èªããæ¬¡ç¬¬ãå ¬è¡šããªããã°ãªããªãããã®æœåšçãªåé¡ã調æ»äžã§ããããšã調æ»ããçµæãããã¯åé¡ã§ããããäžè¬å€§è¡ãåºå¥ã§ããªããšä»®å®ããã®ã¯ãã¹ãã³ãµãŒãèŠå¶åœå±ã幌å åããç¶æš©äž»çŸ©çã§ããããšéªå¯©å£ã¯è¿°ã¹ãã
ãã¡ã€ã¶ãŒç€Ÿãšã¢ãã瀟ã®COVID-19泚å°ã®ææ°ã®èšåºè©Šéšã宿œããããšã
å»è¬åã®æ¶è²»è ãžã®çŽæ¥è²©å£²ãçŠæ¢ããããšã
ã¯ã¯ãã³ã¡ãŒã«ãŒã«å¯ŸããFDAã®èªå¯ãåããåŸãå®å šæ§ãšæå¹æ§ã®ç ç©¶ããåŸãããå¿ååãããåã ã®æ£è ããŒã¿ãéããã«å ¬è¡šããããšã矩åã¥ããã
ã¯ã¯ãã³ã¡ãŒã«ãŒãããŒã¿ã®éææ§èŠä»¶ã«åŸããªãå Žåã®æ³çå è²¬ãæ€å»ããã
äœç³»çãªå€åãšãªãã©ã³ã·ã³ã°ã®çã®åŒã³ãã
éªå¯©å ±åæžã®èè ãã¡ã¯ãCOVID-19ã¯ã¯ãã³ã®å®å šæ§ãšæå¹æ§ãããã£ãŠãå ¬è¡è¡çãå€§è¡æåãã¡ãã£ã¢ã§ç¹°ãåºããããŠããã€ããªãã®ãŒæŠäºãã®ã©ã¡ãã®åŽã«ãç«ã¡ãããªããšè¿°ã¹ãŠããã
COVID-19ã¯ã¯ãã³ããç¡æ°ã®åœãæã£ãç§åŠãæè¡ãå ¬è¡è¡çã®åå©ããšåŒã¶äººãããã°ããç¡é çã«èªå¯ãããéå°ã«å§ããããå¿ èŠã§ãªãåºç¯å²ã®äººã ã«ãŸã§çŸ©åä»ãããã圌ãã®å¥åº·ãæã«ã¯åœãäžå¿ èŠãªå±éºã«ããããããšèšã人ãããã
ã©ã¡ãã®äž»åŒµã«ãçå®ãããããšåœŒãã¯èšãã
ãã®å ±åæžã¯ãã€ããªãã®ãŒæŠäºã®æ°ããªå ¥ãå£ã§ã¯ãªããå¶åºŠæ¹é©ãšãªãã©ã³ã·ã³ã°ãæ±ããçã®åŒã³ãããã§ããããšåœŒãã¯æžããŠããã
ããã®æçµå ±åæžãä»ã«äœãæãéããªããšããŠããç§ãã¡ã¯ããããã®å»è¬åã«é¢ããå€ãã®åŸ®åŠã§å ·äœçãªåé¡ãæç¢ºã«èšè¿°ããæèåããããšã«ãã£ãŠããããã®å»è¬åã«é¢ããå€ãã®åŸ®åŠã§å ·äœçãªåé¡ããããè°è«ãé«ããããšãã§ãããšæ¥œèгèŠããŠãããã
圌ãã®çºèŠãšæèšã¯ããé£éŠèŠå¶åœå±ãå ¬è¡è¡çåœå±ã補è¬ã¹ãã³ãµãŒããããŠç±³åœåžæ°ã®éã®åã®ãã©ã³ã¹ã«é¢ããããã倧ããªæž ç®ã®ããã®éåç ããšãªãããã
The Defenderã¯ãããã«ãã»ãã©ã³ã次æå€§çµ±é ã«ãã£ãŠFDAã®ãããã«æåãããããŒãã£ã»ãã«ãªãŒå士ã«ãéªå¯©å£ã®å ±åæžã«ã€ããŠã®ã³ã¡ã³ããæ±ããããæéãŸã§ã«åçã¯åŸãããªãã£ãã